Phase 2 trial of high-dose rituximab with high-dose cytarabine mobilization therapy and high-dose thiotepa, busulfan, and cyclophosphamide autologous stem cell transplantation in patients with central nervous system involvement by non-Hodgkin lymphoma. [electronic resource]
Producer: 20150309Description: 226-33 p. digitalISSN:- 1097-0142
- Adult
- Aged
- Antibodies, Monoclonal, Murine-Derived -- administration & dosage
- Antineoplastic Combined Chemotherapy Protocols -- adverse effects
- Busulfan -- administration & dosage
- Central Nervous System Neoplasms -- drug therapy
- Cyclophosphamide -- administration & dosage
- Cytarabine -- administration & dosage
- Disease-Free Survival
- Drug Administration Schedule
- Female
- Hematopoietic Stem Cell Transplantation -- methods
- Humans
- Induction Chemotherapy -- methods
- Infusions, Intravenous
- Lymphoma, Non-Hodgkin -- drug therapy
- Male
- Massachusetts
- Middle Aged
- Rituximab
- Thiotepa -- administration & dosage
- Transplantation Conditioning -- methods
- Transplantation, Autologous
No physical items for this record
Publication Type: Clinical Trial, Phase II; Journal Article; Multicenter Study; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
There are no comments on this title.
Log in to your account to post a comment.